IQ EQ FUND MANAGEMENT IRELAND Ltd Increases Holdings in Ionis Pharmaceuticals, Inc. $IONS

IQ EQ FUND MANAGEMENT IRELAND Ltd raised its stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) by 64.6% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 13,263 shares of the company’s stock after purchasing an additional 5,204 shares during the quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd’s holdings in Ionis Pharmaceuticals were worth $524,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. CWM LLC grew its stake in shares of Ionis Pharmaceuticals by 18.7% in the first quarter. CWM LLC now owns 2,435 shares of the company’s stock valued at $73,000 after buying an additional 384 shares in the last quarter. Signaturefd LLC boosted its holdings in Ionis Pharmaceuticals by 45.6% in the 1st quarter. Signaturefd LLC now owns 1,382 shares of the company’s stock worth $42,000 after acquiring an additional 433 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. grew its position in Ionis Pharmaceuticals by 8.5% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 6,135 shares of the company’s stock valued at $185,000 after acquiring an additional 481 shares in the last quarter. Victory Capital Management Inc. raised its stake in shares of Ionis Pharmaceuticals by 3.5% during the first quarter. Victory Capital Management Inc. now owns 18,641 shares of the company’s stock valued at $562,000 after purchasing an additional 637 shares during the period. Finally, GF Fund Management CO. LTD. lifted its position in shares of Ionis Pharmaceuticals by 21.9% during the first quarter. GF Fund Management CO. LTD. now owns 4,042 shares of the company’s stock worth $122,000 after purchasing an additional 727 shares in the last quarter. Institutional investors and hedge funds own 93.86% of the company’s stock.

Ionis Pharmaceuticals Stock Performance

Shares of IONS stock opened at $71.88 on Thursday. The stock has a market capitalization of $11.46 billion, a price-to-earnings ratio of -39.07 and a beta of 0.33. Ionis Pharmaceuticals, Inc. has a one year low of $23.95 and a one year high of $74.42. The company’s 50-day simple moving average is $62.72 and its 200-day simple moving average is $46.02. The company has a debt-to-equity ratio of 0.99, a quick ratio of 2.86 and a current ratio of 2.87.

Ionis Pharmaceuticals (NASDAQ:IONS) last announced its quarterly earnings data on Wednesday, October 29th. The company reported ($0.80) earnings per share for the quarter, beating the consensus estimate of ($1.15) by $0.35. Ionis Pharmaceuticals had a negative return on equity of 45.29% and a negative net margin of 28.25%.The firm had revenue of $157.00 million during the quarter, compared to analyst estimates of $131.75 million. During the same period in the previous year, the company earned ($0.95) earnings per share. Ionis Pharmaceuticals’s quarterly revenue was up 17.2% on a year-over-year basis. Ionis Pharmaceuticals has set its FY 2025 guidance at EPS. Equities analysts anticipate that Ionis Pharmaceuticals, Inc. will post -3.5 earnings per share for the current fiscal year.

Analyst Ratings Changes

IONS has been the subject of a number of recent analyst reports. Jefferies Financial Group raised their price target on shares of Ionis Pharmaceuticals from $83.00 to $96.00 and gave the company a “buy” rating in a report on Tuesday, September 2nd. Royal Bank Of Canada raised their target price on Ionis Pharmaceuticals from $70.00 to $80.00 and gave the company an “outperform” rating in a research note on Thursday, September 4th. Needham & Company LLC lifted their target price on Ionis Pharmaceuticals from $70.00 to $78.00 and gave the stock a “buy” rating in a research report on Wednesday, October 8th. Raymond James Financial set a $75.00 price target on Ionis Pharmaceuticals and gave the company a “strong-buy” rating in a report on Monday, September 22nd. Finally, Guggenheim lifted their price objective on Ionis Pharmaceuticals from $90.00 to $92.00 and gave the stock a “buy” rating in a report on Tuesday, September 23rd. One analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $78.50.

Insider Buying and Selling at Ionis Pharmaceuticals

In related news, CEO Brett P. Monia sold 437 shares of the firm’s stock in a transaction that occurred on Monday, October 6th. The stock was sold at an average price of $69.26, for a total value of $30,266.62. Following the sale, the chief executive officer owned 179,572 shares of the company’s stock, valued at approximately $12,437,156.72. This trade represents a 0.24% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director B Lynne Parshall sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 15th. The shares were sold at an average price of $71.74, for a total value of $358,700.00. Following the transaction, the director owned 61,344 shares of the company’s stock, valued at $4,400,818.56. This represents a 7.54% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 787,770 shares of company stock worth $48,429,221. 2.60% of the stock is owned by insiders.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.